CDK8 kinase - An emerging target in targeted cancer therapy

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1854, Issue 10, 2015, Pages 1617-1629

  Rzymski, Tomasz ^a   Mikula, Michał ^b   Wiklik, Katarzyna ^a   Brzózka, Krzysztof ^a  

^a Selvita Sp   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Cancer; CDK8 kinase; Kinase inhibitors; Novel therapies; Transcription regulation

Indexed keywords

BETA CATENIN; CYCLIN C; CYCLIN DEPENDENT KINASE 8; NOTCH RECEPTOR; PHOSPHOTRANSFERASE INHIBITOR; CARBANILAMIDE DERIVATIVE; CDK8 PROTEIN, HUMAN; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; SORAFENIB;

DNA DAMAGE; DRUG DESIGN; DRUG TARGETING; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; MOLECULARLY TARGETED THERAPY; ONCOGENE; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; NEOPLASMS; PROTEIN CONFORMATION;

CYCLIN-DEPENDENT KINASE 8; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84941811243     PISSN: 15709639     EISSN: 18781454     Source Type: Journal    
DOI: 10.1016/j.bbapap.2015.05.011     Document Type: Review

References (96)

1. M. Loog, and D.O. Morgan Cyclin specificity in the phosphorylation of cyclin-dependent kinase substrates Nature 434 2005 104 108 10.1038/nature03329
2. S. Lapenna, and A. Giordano Cell cycle kinases as therapeutic targets for cancer Nat. Rev. Drug Discov. 8 7 2009 547 566 10.1038/nrd2907
3. U. Asghar, A.K. Witkiewicz, N.C. Turner, and E.S. Knudsen The history and future of targeting cyclin-dependent kinases in cancer therapy Nat. Rev. Drug Discov. 14 2 2015 130 146 10.1038/nrd4504
4. Y.J. Choi, and L. Anders Signaling through cyclin D-dependent kinases Oncogene 33 2014 1890 1903 10.1038/onc.2013.137
5. J.A. Diehl Cycling to cancer with cyclin D1 Cancer Biol. Ther. 1 3 2014 226 231 10.4161/cbt.72
6. S. Lim, and P. Kaldis Cdks, cyclins and CKIs: roles beyond cell cycle regulation Development 140 15 2013 3079 3093 10.1242/dev.091744
7. D.L. Burkhart, and J. Sage Cellular mechanisms of tumour suppression by the retinoblastoma gene Nat. Rev. Cancer 8 9 2008 671 682 10.1038/nrc2399
8. R. Chen, M.J. Keating, V. Gandhi, and W. Plunkett Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death Blood 106 7 2005 2513 2519 10.1182/blood-2005-04-1678
9. L. Cao, F. Chen, X. Yang, W. Xu, J. Xie, and L. Yu Phylogenetic analysis of CDK and cyclin proteins in premetazoan lineages BMC Evol. Biol. 14 2014 10 10.1186/1471-2148-14-10
10. S. Larochelle, R. Amat, K. Glover-Cutter, and et al. Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II Nat. Struct. Mol. Biol. 19 11 2012 1108 1115 10.1038/nsmb.2399
11. M.T. Knuesel, K.D. Meyer, A.J. Donner, J.M. Espinosa, and D.J. Taatjes The human CDK8 subcomplex is a histone kinase that requires Med12 for activity and can function independently of mediator Mol. Cell. Biol. 29 3 2009 650 661 10.1128/MCB.00993-08
12. M.D. Galbraith, A.J. Donner, and J.M. Espinosa CDK8: a positive regulator of transcription Transcription 1 1 2010 4 12 10.4161/trns.1.1.12373
13. J. Bancerek, Z.C. Poss, I. Steinparzer, and et al. CDK8 kinase phosphorylates transcription factor STAT1 to selectively regulate the interferon response Immunity 38 2 2013 250 262 10.1016/j.immuni.2012.10.017
14. J. Zhao, R. Ramos, and M. Demma CDK8 regulates E2F1 transcriptional activity through S375 phosphorylation Oncogene 32 30 2013 3520 3530 10.1038/onc.2012.364
15. R. Firestein, A.J. Bass, S.Y. Kim, and et al. CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity Nature 455 7212 2008 547 551 10.1038/nature07179
16. C. Alarcón, A. Zaromytidou, Q. Xi, and et al. Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways Cell 139 4 2009 757 769 10.1016/j.cell.2009.09.035
17. C.J. Fryer, J.B. White, and K.A. Jones Mastermind recruits CycC:CDK8 to phosphorylate the Notch ICD and coordinate activation with turnover Mol. Cell 16 4 2004 509 520 10.1016/j.molcel.2004.10.014
18. N. Li, A. Fassl, J. Chick, and et al. Cyclin C is a haploinsufficient tumour suppressor Nat. Cell Biol. 16 11 2014 1080 1091 10.1038/ncb3046
19. L. Viladevall, C.V. St Amour, A. Rosebrock, and et al. TFIIH and P-TEFb coordinate transcription with capping enzyme recruitment at specific genes in fission yeast Mol. Cell 33 6 2009 738 751 10.1016/j.molcel.2009.01.029
20. M.W. Nowicki, and M.D. Walkinshaw CDK9 inhibitors push cancer cells over the edge Chem. Biol. 17 10 2010 1047 1048 10.1016/j.chembiol.2010.10.003
21. J. Kohoutek P-TEFb - the final frontier Cell Div. 4 2009 19 10.1186/1747-1028-4-19
22. J. Garriga, H. Xie, and Z. Obradovic Selective control of gene expression by CDK9 in human cells J. Cell 222 1 2010 200 208 10.1002/jcp.21938.Selective
23. R.S. Finn, J.P. Crown, I. Lang, and et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study Lancet Oncol. 16 1 2014 25 35 10.1016/S1470-2045(14)71159-3
24. D. Cai, V.M. Latham, X. Zhang, and G.I. Shapiro Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells Cancer Res. 66 18 2006 9270 9280 10.1158/0008-5472.CAN-06-1758
25. N. Kwiatkowski, T. Zhang, P.B. Rahl, and et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor Nature 2 C 2014 10.1038/nature13393
26. T.K. Albert, C. Rigault, J. Eickhoff, and et al. Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor Br. J. Pharmacol. 171 2014 55 68 10.1111/bph.12408
27. T. Yin, M.J. Lallena, E.L. Kreklau, and et al. A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models Mol. Cancer Ther. 13 2014 1442 1456 10.1158/1535-7163.MCT-13-0849
28. E. Walsby, G. Pratt, H. Shao, and et al. A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine Oncotarget 5 2014 375 385 (Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid = 3964214&tool = pmcentrez&rendertype = abstract.)
29. B. Li, M. Carey, and J.L. Workman The role of chromatin during transcription Cell 128 4 2007 707 719 10.1016/j.cell.2007.01.015
30. M. Heidemann, C. Hintermair, K. Voß, and D. Eick Dynamic phosphorylation patterns of RNA polymerase II CTD during transcription Biochim. Biophys. Acta 1829 1 2013 55 62 10.1016/j.bbagrm.2012.08.013
31. M.T. Knuesel, K.D. Meyer, C. Bernecky, and D.J. Taatjes The human CDK8 subcomplex is a molecular switch that controls mediator coactivator function Genes Dev. 23 2009 439 451 10.1101/gad.1767009
32. C.C. Ebmeier, and D.J. Taatjes Activator-mediator binding regulates mediator-cofactor interactions Proc. Natl. Acad. Sci. U. S. A. 107 25 2010 11283 11288 10.1073/pnas.0914215107
33. R. Pavri, B. Lewis, T.-K. Kim, and et al. PARP-1 determines specificity in a retinoid signaling pathway via direct modulation of mediator Mol. Cell 18 1 2005 83 96 10.1016/j.molcel.2005.02.034
34. H. Takahashi, T.J. Parmely, S. Sato, and et al. Human mediator subunit MED26 functions as a docking site for transcription elongation factors Cell 146 1 2011 92 104 10.1016/j.cell.2011.06.005
35. A.J. Donner, C.C. Ebmeier, D.J. Taatjes, and J.M. Espinosa CDK8 is a positive regulator of transcriptional elongation within the serum response network Nat. Struct. Mol. Biol. 17 2 2010 194 201 10.1038/nsmb.1752
36. M.D. Galbraith, M.A. Allen, C.L. Bensard, and et al. HIF1A employs CDK8-mediator to stimulate RNAPII elongation in response to hypoxia Cell 153 6 2013 1327 1339 10.1016/j.cell.2013.04.048
37. I.S. Strelkov, and J.R. Davie Ser-10 phosphorylation of histone H3 and immediate early gene expression in oncogene-transformed mouse fibroblasts Cancer Res. 62 1 2002 75 78
38. K.D. Meyer, A.J. Donner, M.T. Knuesel, A.G. York, J.M. Espinosa, and D.J. Taatjes Cooperative activity of cdk8 and GCN5L within mediator directs tandem phosphoacetylation of histone H3 EMBO J. 27 10 2008 1447 1457 10.1038/emboj.2008.78
39. F. Lai, U.A. Orom, M. Cesaroni, and et al. Activating RNAs associate with mediator to enhance chromatin architecture and transcription Nature 494 7438 2013 497 501 10.1038/nature11884
40. A.J. Donner, S. Szostek, J.M. Hoover, and J.M. Espinosa CDK8 is a stimulus-specific positive coregulator of p53 target genes Mol. Cell 27 1 2007 121 133 10.1016/j.molcel.2007.05.026
41. T. Westerling, E. Kuuluvainen, and T.P. Mäkelä Cdk8 is essential for preimplantation mouse development Mol. Cell. Biol. 27 17 2007 6177 6182 10.1128/MCB.01302-06
42. A.S. Adler, M.L. McCleland, T. Truong, and et al. CDK8 maintains tumor dedifferentiation and embryonic stem cell pluripotency Cancer Res. 72 8 2012 2129 2139 10.1158/0008-5472.CAN-11-3886
43. M.H. Kagey, J.J. Newman, S. Bilodeau, and et al. Mediator and cohesin connect gene expression and chromatin architecture Nature 467 7314 2010 430 435 10.1038/nature09380
44. R. Firestein, K. Shima, K. Nosho, and et al. CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival Int. J. Cancer 126 12 2010 2863 2873 10.1002/ijc.24908
45. K. Salari, M.E. Spulak, J. Cuff, and et al. CDX2 is an amplified lineage-survival oncogene in colorectal cancer Proc. Natl. Acad. Sci. U. S. A. 109 3 2012 1 10 10.1073/pnas.1206004109
46. E.J. Morris, J.-Y. Ji, F. Yang, and et al. E2F1 represses beta-catenin transcription and is antagonized by both pRB and CDK8 Nature 455 7212 2008 552 556 10.1038/nature07310
47. P.J. Morin Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC Science 275 80- 1997 1787 1790 10.1126/science.275.5307.1787
48. H.H. Luu, R. Zhang, R.C. Haydon, and et al. Wnt/beta-catenin signaling pathway as a novel cancer drug target Curr. Cancer Drug Targets 4 2004 653 671
49. P.J. Morin, A.B. Sparks, V. Korinek, and et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC Science 275 1997 1787 1790 10.1126/science.275.5307.1787
50. T. Valenta, G. Hausmann, and K. Basler The many faces and functions of β-catenin EMBO J. 31 2012 2714 2736 10.1038/emboj.2012.150
51. M. Lepourcelet, Y.-N.P. Chen, D.S. France, and et al. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex Cancer Cell 5 1 2004 91 102 (Available at: http://www.ncbi.nlm.nih.gov/pubmed/14749129)
52. D.C. Porter, E. Farmaki, S. Altilia, and et al. Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities Proc. Natl. Acad. Sci. U. S. A. 109 34 2012 1 6 10.1073/pnas.1206906109
53. T. Tsutsui, R. Fukasawa, A. Tanaka, Y. Hirose, and Y. Ohkuma Identification of target genes for the CDK subunits of the mediator complex Genes Cells 2011 1208 1218 10.1111/j.1365-2443.2011.01565.x
54. S. Healy, P. Khan, and J.R. Davie Immediate early response genes and cell transformation Pharmacol. Ther. 137 1 2013 64 77 10.1016/j.pharmthera.2012.09.001
55. A.L. Gartel Is p21 an oncogene? Mol. Cancer Ther. 5 6 2006 1385 1386 10.1158/1535-7163.MCT-06-0163
56. L.A. Gilbert, and M.T. Hemann DNA damage-mediated induction of a chemoresistant niche Cell 143 3 2010 355 366 10.1016/j.cell.2010.09.043
57. B.D. Chang, K. Watanabe, E.V. Broude, and et al. Effects of p21Waf1/Cip1/Sdi1 on cellular gene expression: implications for carcinogenesis, senescence, and age-related diseases Proc. Natl. Acad. Sci. U. S. A. 97 8 2000 4291 4296 10.1073/pnas.97.8.4291
58. L. Klampfer Signal transducers and activators of transcription (STATs): novel targets of chemopreventive and chemotherapeutic drugs Curr. Cancer Drug Targets 6 2 2006 107 121 (107-21. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16529541)
59. L.M. Hix, J. Karavitis, M.W. Khan, Y.H. Shi, K. Khazaie, and M. Zhang Tumor STAT1 transcription factor activity enhances breast tumor growth and immune suppression mediated by myeloid-derived suppressor cells J. Biol. Chem. 288 17 2013 11676 11688 10.1074/jbc.M112.441402
60. N.N. Khodarev, B. Roizman, and R.R. Weichselbaum Molecular pathways: interferon/stat1 pathway: role in the tumor resistance to genotoxic stress and aggressive growth Clin. Cancer Res. 18 11 2012 3015 3021 10.1158/1078-0432.CCR-11-3225
61. J.-P. Spano, G. Milano, C. Rixe, and R. Fagard JAK/STAT signalling pathway in colorectal cancer: a new biological target with therapeutic implications Eur. J. Cancer 42 16 2006 2668 2670 10.1016/j.ejca.2006.07.006
62. C.W. Duarte, C.D. Willey, D. Zhi, and et al. Expression signature of IFN/STAT1 signaling genes predicts poor survival outcome in glioblastoma multiforme in a subtype-specific manner PLoS One 7 1 2012 e29653 10.1371/journal.pone.0029653
63. N.N. Khodarev, P. Roach, S.P. Pitroda, and et al. STAT1 pathway mediates amplification of metastatic potential and resistance to therapy PLoS One 4 6 2009 e5821 10.1371/journal.pone.0005821
64. O.A. Timofeeva, S. Plisov, and A.A. Evseev Serine-phosphorylated STAT1 is a prosurvival factor in Wilms' tumor pathogenesis Oncogene 25 58 2006 7555 7564 10.1038/sj.onc.1209742
65. N.N. Khodarev, M. Beckett, E. Labay, T. Darga, B. Roizman, and R.R. Weichselbaum STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells Proc. Natl. Acad. Sci. U. S. A. 101 6 2004 1714 1719 10.1073/pnas.0308102100
66. E.M. Putz, D. Gotthardt, G. Hoermann, and et al. CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance Cell Rep. 2013 437 444 10.1016/j.celrep.2013.07.012
67. X.-H. Feng, and R. Derynck Specificity and versatility in tgf-beta signaling through Smads Annu. Rev. Cell Dev. Biol. 21 2005 659 693 10.1146/annurev.cellbio.21.022404.142018
68. U. Koch, and F. Radtke Mechanisms of T cell development and transformation Annu. Rev. Cell Dev. Biol. 27 2011 539 562 10.1146/annurev-cellbio-092910-154008
69. E.V. Schneider, J. Böttcher, M. Blaesse, L. Neumann, R. Huber, and K. Maskos The structure of CDK8/CycC implicates specificity in the CDK/cyclin family and reveals interaction with a deep pocket binder J. Mol. Biol. 412 2 2011 251 266 10.1016/j.jmb.2011.07.020
70. H.M. Berman, G.J. Kleywegt, H. Nakamura, and J.L. Markley The Protein Data Bank archive as an open data resource J. Comput. Aided Mol. Des. 2014 1009 1014 10.1007/s10822-014-9770-y
71. J. Grey, and D. Thompson Challenges and opportunities for new protein crystallization strategies in structure-based drug design Challenges 5 11 2011 1039 1045 10.1517/17460441.2010.515583
72. M. Rabiller, M. Getlik, S. Klüter, and et al. Proteus in the world of proteins: conformational changes in protein kinases Arch. Pharm. 343 4 2010 193 206 10.1002/ardp.201000028
73. V.J. Cee, D.Y.-K. Chen, M.R. Lee, and K.C. Nicolaou Cortistatin A is a high-affinity ligand of protein kinases ROCK, CDK8, and CDK11 Angew. Chem. Int. Ed. Engl. 48 47 2009 8952 8957 10.1002/anie.200904778
74. J.A. Endicott Noble MEM. Structural characterization of the cyclin-dependent protein kinase family Biochem. Soc. Trans. 41 2013 1008 1016 10.1042/BST20130097
75. F.S. Oppermann, F. Gnad, J.V. Olsen, and et al. Large-scale proteomics analysis of the human kinome Mol. Cell. Proteomics 8 2009 1751 1764 10.1074/mcp.M800588-MCP200
76. P.J. Tummino, and R.A. Copeland Residence time of receptor-ligand complexes and its effect on biological function Biochemistry 47 20 2008 5481 5492 10.1021/bi8002023
77. M.W. Karaman, S. Herrgard, D.K. Treiber, and et al. A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 26 1 2008 127 132 10.1038/nbt1358
78. M.I. Davis, J.P. Hunt, S. Herrgard, and et al. Comprehensive analysis of kinase inhibitor selectivity Nat. Biotechnol. 29 11 2011 1046 1051 10.1038/nbt.1990
79. L. Daniels D Mutual exclusivity of MED12/MED12L, MED13/13L, and CDK8/19 paralogs revealed within the CDK-mediator kinase module J. Proteom. Bioinforma. 01 S2 2013 10.4172/jpb.S2-004
80. H.M. Shallal, and W.A. Russu Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives Eur. J. Med. Chem. 46 6 2011 2043 2057 10.1016/j.ejmech.2011.02.057
81. W.S. Palmer, M. Alam, H.B. Arzeno, and et al. Development of amino-pyrimidine inhibitors of c-Jun N-terminal kinase (JNK): kinase profiling guided optimization of a 1,2,3-benzotriazole lead Bioorg. Med. Chem. Lett. 23 5 2013 1486 1492 10.1016/j.bmcl.2012.12.047
82. M. Getlik, C. Grütter, J.R. Simard, and et al. Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc J. Med. Chem. 52 2009 3915 3926 10.1021/jm9002928
83. T. Saurat, F. Buron, N. Rodrigues, and et al. Design, synthesis, and biological activity of pyridopyrimidine scaffolds as novel PI3K/mTOR dual inhibitors J. Med. Chem. 57 2014 613 631 10.1021/jm401138v
84. D.C. Porter, E. Farmaki, S. Altilia, and et al. Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities Proc. Natl. Acad. Sci. 109 34 2012 13799 13804 10.1073/pnas.1206906109
85. P.D. Jeffrey, A.A. Russo, K. Polyak, E. Gibbs, J. Hurwitz, J. Massague, and N.P. Pavletich Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex Nature 376 6538 1995 313 320 10.1038/376313a0
86. M. Noble, P. Barrett, J. Endicott, L. Johnson, J. McDonnell, G. Robertson, and A. Zawaira Exploiting structural principles to design cyclin-dependent kinase inhibitors Biochimica et Biophysica Acta - Proteins and Proteomics 1754 2005 58 64 10.1016/j.bbapap.2005.08.019
87. S.M. Liao, J. Zhang, D.A. Jeffery, A.J. Koleske, C.M. Thompson, D.M. Chao, and R.A. Young A kinase-cyclin pair in the RNA polymerase II holoenzyme Nature 374 6518 1995 193 196 10.1038/374193a0
88. H. Elmlund, V. Baraznenok, M. Lindahl, C.O. Samuelsen, P.J.B. Koeck, S. Holmberg, and C.M. Gustafsson The cyclin-dependent kinase 8 module sterically blocks Mediator interactions with RNA polymerase II Proceedings of the National Academy of Sciences of the United States of America 103 43 2006 15788 15793 10.1073/pnas.0607483103
89. X. Wang, J. Wang, Z. Ding, J. Ji, Q. Sun, and G. Cai Structural flexibility and functional interaction of mediator Cdk8 module Protein and Cell 4 12 2013 911 920 10.1007/s13238-013-3069-y
90. Kuang-Lei Tsai, Shigeo Sato, Chieri Tomomori-Sato, J.W. Ronald C. Conaway, and F.J.A. Conaway A conserved Mediator-CDK8 kinase module association regulates Mediator-RNA polymerase II interaction Nat. Struct. Mol. Biol 20 5 2013 611 619 10.1016/j.biotechadv.2011.08.021.Secreted
91. M. Malumbres, E. Harlow, T. Hunt, T. Hunter, J.M. Lahti, G. Manning, and D.J. Wolgemuth Cyclin-dependent kinases: a family portrait Nat. Cell Biol. 11 11 2009 1275 1276 10.1038/ncb1109-1275
92. S. Sato, C. Tomomori-Sato, T.J. Parmely, L. Florens, B. Zybailov, S.K. Swanson, and R.C. Conaway A set of consensus mammalian mediator subunits identified by multidimensional protein identification technology Mol. Cell 14 5 2004 685 691 10.1016/j.molcel.2004.05.006
93. T. Tsutsui, H. Umemura, A. Tanaka, F. Mizuki, Y. Hirose, and Y. Ohkuma Human mediator kinase subunit CDK11 plays a negative role in viral activator VP16-dependent transcriptional regulation Genes to Cells 13 8 2008 817 826 10.1111/j.1365-2443.2008.01208.x
94. T. Furumoto, A. Tanaka, M. Ito, S. Malik, Y. Hirose, F. Hanaoka, and Y. Ohkuma A kinase subunit of the human mediator complex, CDK8, positively regulates transcriptional activation Genes to Cells 12 1 2007 119 132 10.1111/j.1365-2443.2007.01036.x
95. R. Fukasawa, T. Tsutsui, Y. Hirose, A. Tanaka, and Y. Ohkuma Mediator CDK subunits are platforms for interactions with various chromatin regulatory complexes J. Biochem. 152 3 2012 241 249 10.1093/jb/mvs065
96. E. Schneider, J. Böttcher, R. Huber, K. Maskos, and L. Neumann Structure-kinetic relationship study of CDK8/CycC specific compounds PNAS 110 20 2013 8081 8086 10.1073/pnas.1305378110